India Ratings upgraded Shilpa Medicare and its subsidiary Shilpa Pharma Lifesciences' credit ratings to 'IND AA-/Stable'. Shilpa Pharma also repaid 750 million INR in NCDs, leading to rating withdrawal for that instrument. This signals stronger financial health.
Shilpa Medicare Credit Rating Upgraded by India Ratings
Shilpa Medicare Limited's credit rating has been upgraded to 'IND AA-/Stable' by India Ratings and Research, signalling enhanced financial stability and a lower credit risk. The rating agency also upgraded its material subsidiary, Shilpa Pharma Lifesciences Limited, to the same 'IND AA-/Stable' for long-term facilities and 'IND A1+' for short-term facilities.
What just happened
Shilpa Medicare Limited's bank loan facilities were upgraded to IND AA-/Stable/IND A1+ from IND A+/Positive/IND A1. Shilpa Pharma Lifesciences Limited's long-term bank facilities saw an upgrade to IND AA-/Stable from IND A+, and its short-term bank facilities were upgraded to IND A1+ from IND A1.
Why this matters
This upgrade suggests improved creditworthiness for Shilpa Medicare and its subsidiary, potentially leading to better access to capital and lower borrowing costs. The upgrade to 'IND AA-' indicates a high degree of safety for their financial obligations.
The backstory
Previously, Shilpa Medicare Limited's bank loan facilities were rated 'IND A+/Positive/IND A1', and Shilpa Pharma Lifesciences' long-term and short-term facilities were rated 'IND A+' and 'IND A1' respectively. The upgrade reflects a positive shift in the companies' financial standing over the review period.
What changes now
Shilpa Medicare and Shilpa Pharma Lifesciences are now perceived to have a stronger ability to meet their financial commitments. This enhanced rating could positively influence their ability to secure future funding on more favourable terms.
Risks to watch
While the upgrade is positive, investors should monitor the company's debt levels and interest coverage ratios to ensure sustained financial discipline. The company's ability to leverage this improved rating for growth without excessive risk will be key.
Peer comparison
Companies with 'IND AA-' ratings typically demonstrate robust financial performance and strong market positions. Shilpa Medicare's move into this category places it among entities with a high safety margin for debt repayment.
Context metrics (time-bound)
Shilpa Pharma Lifesciences Limited successfully repaid its outstanding Non-convertible debentures (NCDs) amounting to 750 million INR. India Ratings has withdrawn the credit rating for these specific NCDs following their full repayment.
What to track next
Investors should observe how Shilpa Medicare and Shilpa Pharma Lifesciences utilize their strengthened credit profile. Key indicators to track include future borrowing plans, interest expenses, and overall financial leverage.